BOSTON (TheStreet) -- Biotech stocks continued to march higher at a torrid pace in the first quarter, with the Nasdaq Biotechnology Index (NBI) up 15% compared to a 10% rise in the S&P 500. In fact, the NBI is now comfortably at an all-time high, even higher today that it was during the crazy dot-com and genomics bubble of 1999-2000.
The best way for investors to profit from biotech trading is by staying on top of the most important stock-moving events. To make this job easier, I compiled a list of the most significant biotech trading catalysts for the second quarter. Happy trading!
Sarepta Therapeutics (SRPT): Decision on the accelerated approval filing for eteplirsen to treat patients with Duchenne Muscular Dystrophy (exon 51.) Sarepta met with FDA late last month to discuss the eteplirsen filing, so expect a public announcement towards the end of April.
Zogenix (ZGNX): FDA approval decision for Zohydro, an extended-release formulation of the chronic pain drug hydrocodone without acetaminophen. A decision could come at any time following a delay of the original March 1 PDUFA date.Arena Pharmaceuticals (ARNA): The U.S. commercial launch of the weight-loss pill Belviq in April plus a possible approval decision by European regulators. Delcath Systems (DCTH): FDA advisory panel reviewing Melblez on May 2. The FDA approval decision is expected on June 14. Aveo Pharmaceuticals (AVEO): FDA advisory panel reviewing Tivozanib also on May 2. Vivus (VVUS): FDA decision expected in April on loosening marketing restrictions on the weight-loss pill Qsymia, including allowing the drug to be sold in retail pharmacies. Titan Pharmaceuticals (TTNP): FDA approval decision for Probuphine on April 30. Don't be surprised if the decision is delayed three months because Titan and FDA are still working on a final risk management plan. Hepatitis C drug stocks: The European Association for the Study of Liver Disease (EASL) will release research abstracts for its closely spring meeting on April 8. [The actual EASL meeting is held April 24-28.] Investor focus will be on new and updated data from Gilead Sciences (GILD), Achillion Pharmaceuticals (ACHN), Bristol-Myers Squibb (BMY), Merck (MRK), Abbvie (ABBV) and others.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV